Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
J Crohns Colitis. 2022 Feb 23;16(2):275-285. doi: 10.1093/ecco-jcc/jjab131.
Genome-wide association studies [GWAS] for inflammatory bowel disease [IBD] have identified 240 risk variants. However, the benefit of understanding the genetic architecture of IBD remains to be exploited. Transcriptome-wide association studies [TWAS] associate gene expression with genetic susceptibility to disease, providing functional insight into risk loci. In this study, we integrate relevant datasets for IBD and perform a TWAS to nominate novel genes implicated in IBD genetic susceptibility.
We applied elastic net regression to generate gene expression prediction models for the University of Barcelona and University of Virginia RNA sequencing project [BarcUVa-Seq] and correlated expression and disease association research [CEDAR] datasets. Together with Genotype-Tissue Expression project [GTEx] data, and GWAS results from about 60 000 individuals, we employed Summary-PrediXcan and Summary-MultiXcan for single and joint analyses of TWAS results, respectively.
BarcUVa-Seq TWAS revealed 39 novel genes whose expression in the colon is associated with IBD genetic susceptibility. They included expression markers for specific colon cell types. TWAS meta-analysis including all tissues/cell types provided 186 novel candidate susceptibility genes. Additionally, we identified 78 novel susceptibility genes whose expression is associated with IBD exclusively in immune (N = 19), epithelial (N = 25), mesenchymal (N = 22) and neural (N = 12) tissue categories. Associated genes were involved in relevant molecular pathways, including pathways related to known IBD therapeutics, such as tumour necrosis factor signalling.
These findings provide insight into tissue-specific molecular processes underlying IBD genetic susceptibility. Associated genes could be candidate targets for new therapeutics and should be prioritized in functional studies.
全基因组关联研究(GWAS)已经确定了 240 个炎症性肠病(IBD)的风险变异。然而,了解 IBD 的遗传结构的益处仍有待开发。全转录组关联研究(TWAS)将基因表达与疾病的遗传易感性联系起来,为风险基因座提供了功能上的见解。在这项研究中,我们整合了 IBD 的相关数据集,并进行了 TWAS,以提名与 IBD 遗传易感性相关的新基因。
我们应用弹性网络回归为巴塞罗那大学和弗吉尼亚大学 RNA 测序项目(BarcUVa-Seq)和关联表达和疾病关联研究(CEDAR)数据集生成基因表达预测模型。结合基因型-组织表达项目(GTEx)的数据和来自约 60000 个人的 GWAS 结果,我们分别使用 Summary-PrediXcan 和 Summary-MultiXcan 进行 TWAS 结果的单分析和联合分析。
BarcUVa-Seq TWAS 揭示了 39 个新基因,它们在结肠中的表达与 IBD 的遗传易感性相关。其中包括特定结肠细胞类型的表达标志物。包括所有组织/细胞类型的 TWAS 荟萃分析提供了 186 个新的候选易感性基因。此外,我们还发现了 78 个新的易感性基因,它们的表达仅与免疫(N = 19)、上皮(N = 25)、间充质(N = 22)和神经(N = 12)组织类别中的 IBD 相关。相关基因参与了相关的分子途径,包括与已知的 IBD 治疗药物相关的途径,如肿瘤坏死因子信号。
这些发现提供了对 IBD 遗传易感性的组织特异性分子过程的深入了解。相关基因可能是新治疗药物的候选靶点,应在功能研究中优先考虑。